Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03644485
Other study ID # 506-MA-3186
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 21, 2018
Est. completion date July 15, 2022

Study information

Verified date December 2023
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment groups: delayed or standard Prograf together with induction therapy, and then convert to Advagraf usage in donation after cardiac (or circulatory) death (DCD) kidney transplant recipients. This study will also compare the clinical outcome within 6 month post-transplant between the 2 IS treatment groups and compare the safety throughout study period between the 2 IS treatment groups.


Recruitment information / eligibility

Status Completed
Enrollment 284
Est. completion date July 15, 2022
Est. primary completion date July 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Subject has end-stage kidney disease who is a suitable candidate for primary DCD kidney transplantation. - Subject is a resident of China. - Subject is scheduled to undergo DCD renal allograft transplantation with compatible ABO blood type. - Subject has peak panel-reactive antibodies (PRA) < 10% or "Negative" test result. - Subject must be a recipient of a DCD kidney and receive the organ distributed by China Organ Transplant Response System only. - Female subject must either: - Be of non-childbearing potential: Postmenopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile - Or, if of childbearing potential: Agree not to try to become pregnant throughout the study period and have a negative blood pregnancy test at screening. - A sexually active male or female subject is utilizing highly effective forms of birth control starting at screening and throughout the study period if the risk of conception exists. - Subject agrees not to participate in another interventional study while participating in the present study from 1 month before randomization to 1 month after the last dose of investigational drug. Exclusion Criteria: - Subject has previously received or is receiving an organ transplant other than kidney. - Subject is receiving double-kidney transplant. - Recipients of Maastricht Class I, II, and V donor organs. - Recipients of Maastricht Class III and IV donor organs without a full complement of intensive care unit and intraoperative records. - Subject has cold ischemia time of allograft > 24 hours before kidney transplantation surgery. - Subject has known contraindication to administration of tacrolimus (Prograf or Advagraf), or other macrolides. - Subject is unlikely to comply with the visits scheduled in the protocol or has a history of non-compliance. - Subject has evidence of active liver disease or the presence of a chronic active hepatitis B or C within 1 month prior to kidney transplant surgery. - Recipient or donor is seropositive for human immunodeficiency virus. - Subject has active systemic infection requiring the use of antimicrobial agents within 1 week prior to kidney transplant surgery. - Subject has current malignancy or a history of malignancy (within the past 5 years), except non- metastatic basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix that has been treated successfully. - Subject has medical or psychological conditions which would preclude compliance with the study requirements. - Subject has any condition, including any uncontrolled disease state other than end-stage kidney disease, that constitutes an inappropriate risk or a contraindication for participation in the study, or that could interfere with the study objectives, conduction, or evaluation. - Female subject who breastfeed or donate ova starting at screening and throughout the study period. - Male subject who donate sperm starting at screening and throughout the study period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tacrolimus immediate-release formulation
oral
Tacrolimus prolonged-release formulation
oral
Induction therapy
All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
Mycophenolic acid drugs
All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
Corticosteroids
All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.

Locations

Country Name City State
China Site CN08608 Beijing
China Site CN08619 Beijing
China Site CN08609 Changsha
China Site CN08604 Guangzhou
China Site CN08614 Hangzhou
China Site CN08617 Hangzhou
China Site CN08610 Nanjing
China Site CN08618 Nanjing
China Site CN08612 Shanghai
China Site CN08603 Tianjin
China Site CN08621 Wenzhou
China Site CN08602 Wuhan
China Site CN08613 Wuhan
China Site CN08605 Xi'an

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma China, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of delayed graft function (DGF) DGF is defined as dialysis requirement during the first post-transplant week (7 days). Up to Day 7 after transplantation
Secondary Incidence of acute rejection (AR) The reporting of AR includes any biopsy-proven or clinically-suspected rejection of a subject after transplantation. Up to Month 6 after transplantation
Secondary Renal function assessed by estimated glomerular filtration rate (eGFR) eGFR will be derived using the abbreviated Modification of Diet in Renal Disease (MDRD) formula. Up to Month 6 after transplantation
Secondary Renal function assessed by serum creatinine Serum creatinine will be measured from serum sample collected. Up to Month 6 after transplantation
Secondary Renal function assessed by urea nitrogen Urea nitrogen will be measured from serum sample collected. Up to Month 6 after transplantation
Secondary Subject survival Subject survival is the time from the date of transplantation to the date of death or the date of the last follow-up. Subject survival will be estimated using Kaplan Meier estimates and compared by log rank test. Up to Month 6 after transplantation
Secondary Graft survival Graft survival is an estimate of the probability of the transplant functioning at a finite time after transplantation. Graft survival will be calculated from the date of transplantation to the date of irreversible graft failure or the date of the last follow-up during the period when the transplant is still functioning or to the date of death. Up to Month 6 after transplantation
Secondary Safety assessed by incidence of treatment-emergent adverse events (TEAEs) Adverse events (AEs) will be coded using the latest version of MedDRA. TEAE is defined as any AE following the transplantation until the end of the study. Up to Month 7 after transplantation
Secondary Safety assessed by incidence of serious adverse events (SAEs) AE is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event. Up to Month 7 after transplantation
Secondary Number of participants with laboratory test abnormalities and/or AEs Number of participants with potentially clinically significant laboratory values. Up to Month 7 after transplantation
Secondary Number of participants with vital sign abnormalities and/or AEs Number of participants with potentially clinically significant vital sign values. Up to Month 7 after transplantation
Secondary Number of participants with 12-lead electrocardiograms (ECG) abnormalities and/or AEs ECG will be performed in the supine position after the subject has been breathing quietly for 5 minutes. Any clinically significant adverse changes on the ECG will be reported as AEs. Up to Month 7 after transplantation
See also
  Status Clinical Trial Phase
Completed NCT04087720 - Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant Phase 4
Completed NCT03749356 - Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients Phase 4
Withdrawn NCT05811468 - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT00498576 - Melatonin and Adiponectin in Hypertensive Kidney Transplant N/A
Completed NCT00642655 - Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation Phase 1/Phase 2
Completed NCT00374400 - The Paired Donation Consortium Paired Donation Program N/A
Completed NCT01710033 - A Study Of CP-690,550 In Stable Kidney Transplant Patients Phase 1
Completed NCT00205257 - Prediction of Acute Rejection in Renal Transplant Phase 1
Completed NCT02711826 - Treg Therapy in Subclinical Inflammation in Kidney Transplantation Phase 1/Phase 2
Withdrawn NCT03978494 - Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients. Phase 1
Completed NCT03837522 - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies N/A
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT05029310 - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients Phase 4
Active, not recruiting NCT02409901 - Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients N/A
Completed NCT01047410 - ACtive Care After Transplantation, the ACT Study N/A
Completed NCT00940940 - Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Phase 4
Completed NCT00270712 - A Study of Factors That Affect Long-Term Kidney Transplant Function
Completed NCT00217126 - The Study of Long-term Deterioration of Kidney Transplants. Phase 4
Completed NCT00171496 - Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients Phase 4